Physician profile
Jonathan B Stone
NPI 1154437937
$2,326.62
in general payments reported to CMS, 2019-2025
27 companies · $257 in 2025
The $257 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $523 · 2020: $291 · 2021: $414 · 2022: $305 · 2023: $431 · 2024: $105 · 2025: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $793.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $503.74 | 2019-2025 | Belbuca, Xtampza |
| Arbor Pharmaceuticals, INC. | $352.94 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $344.75 | 2022-2023 | Belsomra, Lagevrio |
| Pfizer INC. | $159.03 | 2019-2021 | |
| Forte Bio-Pharma LLC | $140.14 | 2022-2025 | Prolate, Nalocet, Tanlor |
| Scilex Pharmaceuticals INC. | $108.17 | 2019-2021 | |
| Medtronic USA, INC. | $100.65 | 2019 | |
| Biodelivery Sciences International, INC. | $95.69 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.18 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $48.09 | 2025 | Quviviq |
| Eisai INC. | $45.50 | 2021 | |
| Medtronic, INC. | $44.98 | 2025 | Inceptiv |
| Almatica Pharma LLC | $35.92 | 2023 | Gralise |
| Redhill Biopharma INC. | $27.90 | 2021-2022 | |
| Virtus Pharmaceuticals LLC | $27.77 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $25.11 | 2022 | |
| Sentynl Therapeutics, INC. | $24.65 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $21.58 | 2025 | |
| Abbvie INC. | $19.99 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $19.47 | 2025 | Iovera, Zilretta |
| Nalu Medical, INC. | $18.25 | 2023 | Nalu Neurostimulation System |
| Shionogi INC | $18.15 | 2019 | |
| Tonix Medicines, INC. | $16.90 | 2025 | Tonmya |
| Metacel Pharmaceuticals LLC | $16.83 | 2022 | |
| Amniox Medical, INC. | $13.75 | 2019 | |
| Protega Pharmaceutials INC | $13.75 | 2025 | Roxybond |
| Assertio Therapeutics, INC. | $13.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.